Other combinations of dual ICIs, including durvalumab (an anti-PD-L1 agent) plus tremelimumab (a CTLA-4 inhibitor) (EMERALD-2; HIMALAYA), are under clinical investigation in HCC (69). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.